INM
NASDAQInMed Pharmaceuticals Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
News · 26 weeks38+133%
2025-12-072026-05-31
Mix1890d
- SEC Filings13(72%)
- Offering2(11%)
- Insider2(11%)
- Other1(6%)
Latest news
25 items- INSIDERLarge owner Adar1 Capital Management, Llc bought $721,548 worth of shares (468,551 units at $1.54) (SEC Form 4)4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)
- INSIDERNew insider Adar1 Capital Management, Llc claimed ownership of 331,449 shares (SEC Form 3)3 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)
- PR/C O R R E C T I O N -- InMed Pharmaceuticals/In the news release, InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies, issued 19-May-2026 by InMed Pharmaceuticals over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end: InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies Mentari's parallel lead programs target validated, complementary pathways with potential to address the two-thirds of patients who have a suboptimal response to anti-CGRP therapiesConcurrent oversubscribed US$290 million private placement of Mentari expected to fund company o
- SECSEC Form 425 filed by InMed Pharmaceuticals Inc.425 - InMed Pharmaceuticals Inc. (0001728328) (Subject)
- SECInMed Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)
- PRInMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention TherapiesMentari's parallel lead programs target validated, complementary pathways with potential to address the two-thirds of patients who have a suboptimal response to anti-CGRP therapiesConcurrent oversubscribed US$290 million private placement of Mentari expected to fund company operations through 2028First-in-human regulatory filings for MT-001 (anti-PACAP) and MT-002 (anti-CGRP x PACAP bispecific) expected mid-2026 and 1Q 2027, respectivelyConference call scheduled for May 19, 2026, at 8:30 AM EDTVANCOUVER, BC and SAN FRANCISCO, May 19, 2026 /PRNewswire/ -- InMed Pharmaceuticals, Inc. (NASDAQ:INM) ("InMed" or the "Company") is pleased to announce that it has entered into a definitive merger agr
- SECInMed Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Other Events, Financial Statements and Exhibits8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)
- SECSEC Form 10-Q filed by InMed Pharmaceuticals Inc.10-Q - InMed Pharmaceuticals Inc. (0001728328) (Filer)
- PRInMed Pharmaceuticals Amends Preferred Investment OptionsVancouver, British Columbia--(Newsfile Corp. - April 27, 2026) - InMed Pharmaceuticals Inc. (NASDAQ:INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announces that it has entered into amending agreements in respect of preferred investment options previously entered into with each of Sabby Volatility Warrant Master Fund, Ltd. ("Sabby") and certain affiliates of H.C. Wainwright & Co., LLC (the "Wainwright Parties").As previously reported: pursuant to the terms of the preferred investment options dated October 26, 2023 and June 26, 2025 (together, the "Sabby
- SECInMed Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Other Events, Financial Statements and Exhibits8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)
- SECInMed Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)
- SECSEC Form 424B5 filed by InMed Pharmaceuticals Inc.424B5 - InMed Pharmaceuticals Inc. (0001728328) (Filer)
- SECSEC Form EFFECT filed by InMed Pharmaceuticals Inc.EFFECT - InMed Pharmaceuticals Inc. (0001728328) (Filer)
- SECInMed Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)
- SECInMed Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)
- SECSEC Form S-3 filed by InMed Pharmaceuticals Inc.S-3 - InMed Pharmaceuticals Inc. (0001728328) (Filer)
- SECInMed Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)
- SECInMed Pharmaceuticals Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)
- SECInMed Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)
- SECSEC Form 10-Q filed by InMed Pharmaceuticals Inc.10-Q - InMed Pharmaceuticals Inc. (0001728328) (Filer)
- SECSEC Form SCHEDULE 13G filed by InMed Pharmaceuticals Inc.SCHEDULE 13G - InMed Pharmaceuticals Inc. (0001728328) (Subject)
- INSIDERSEC Form 4 filed by Sr VP & General Manager Johnson Shane Aaron4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)
- INSIDERSEC Form 4 filed by Director Lemerond Nicole4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)
- INSIDERSEC Form 4 filed by Director Klompas Neil A4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Jagpal Netta4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)
INM FAQ
6 questionsWhat does InMed Pharmaceuticals Inc. do?
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the...Where does INM stock trade?
InMed Pharmaceuticals Inc. (INM) is listed on NASDAQ.What sector and industry is INM in?
InMed Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about INM?
InMed Pharmaceuticals Inc. has had 1 recent analyst action on file. The most recent action was from HC Wainwright & Co.: Buy with a $600.00 price target on 2021-11-29. Recent price targets cluster around $600.00.What companies are similar to INM?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare INM side-by-side with any of them on Quantisnow.How can I track INM on Quantisnow?
Quantisnow aggregates InMed Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow INM to receive live email and push alerts on every new disclosure.